Transporting silence: design of carriers for siRNA to angiogenic endothelium.
The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis.
Schiffelers
Raymond M
RM
Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands. r.m.schiffelers@pharm.uu.nl
Mixson
Archibald J
AJ
Ansari
Aslam M
AM
Fens
Marcel H A M
MH
Tang
Quingquan
Q
Zhou
Qin
Q
Xu
Jun
J
Molema
Grietje
G
Lu
Patrick Y
PY
Scaria
Puthupparampil V
PV
Storm
Gert
G
Woodle
Martin C
MC
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D002478:Cells, Cultured; D016503:Drug Delivery Systems; D005434:Flow Cytometry; D006801:Humans; D007202:Indicators and Reagents; D051379:Mice; D008807:Mice, Inbred BALB C; D008856:Microscopy, Fluorescence; D009389:Neovascularization, Pathologic / Q000628:therapy*; D009842:Oligopeptides / Q000008:administration & dosage / Q000737:chemistry; D010455:Peptides / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D007202:Indicators and Reagents; D009842:Oligopeptides; D010455:Peptides; D010714:Phosphatidylethanolamines; D034741:RNA, Small Interfering; C094877:dioleoyl phosphatidylethanolamine; D011092:Polyethylene Glycols; C047981:arginyl-glycyl-aspartic acid